探索试验中对主要终点的影响,以检测类风湿性关节炎的向治疗干预措施:关于适当使用核心结果集的超流行病学研究
Philip Rask Lage-Hansen1,2,3, Nikoletta Svendsen4, Jamie Kirkham5
1Department of Rheumatology, Esbjerg and Grindsted Hospital, Esbjerg, Denmark philip.rask.lage-hansen3@rsyd.dk.
Annals of the rheumatic diseases
|May 22, 2024
概括
身体残疾和疲劳是类风湿性关节炎治疗反应的关键因素. 这些核心领域的改善与美国风湿病学学院的20%反应有显著的相关性,这突显了它们在临床试验中的重要性.
科学领域:
- 类风湿病学 类风湿病学
- 临床试验 临床试验
- 超流行病学 超流行病学
背景情况:
- 风湿性关节炎 (RA) 试验使用美国风湿病学会 (ACR) 20%的反应作为主要终点.
- 了解个别核心领域对这种反应的贡献,对于准确的试验解释至关重要.
研究的目的:
- 在类风湿性关节炎试验中,确定哪个核心领域与ACR 20%反应最好相关.
- 评估针对性干预对RA结果的影响.
主要方法:
- 一项超流行病学研究分析了115项针对性RA干预的随机试验与安慰剂或常规疾病修饰性抗风湿药物相比.
- 结果措施包括ACR 20%响应的几率比率和八个核心领域的标准化平均差异.
主要成果:
- 20%的ACR反应与实验干预显著相关 (OR 3.19).
- 所有八个核心领域都显示出与ACR 20%响应的显著关联.
- 身体残疾的改善最强烈地解释了ACR20%的整体反应,而当所有八个核心领域都报告时,疲劳最为显著.
结论:
- 缺失数据的数量和特征显著影响了研究结论.
- 疲劳可能是RA试验中主要终点的更关键因素,而不是以前承认的,尽管基于有限的数据.
相关概念视频
Clinical Trials: Overview
2.9K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.9K
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
131
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
131
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
125
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
125
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
421
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
421
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
158
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
158


